Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBIPQL)

Drug Name
Enavatuzumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMBIPQL

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
TNF superfamily receptor 12A (TNFRSF12A) TTKPS7V TNR12_HUMAN Not Available [1]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
TNF superfamily receptor 12A (TNFRSF12A) DTT TNFRSF12A 7.6 5.781 7.253 7.284
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
TNF superfamily receptor 12A (TNFRSF12A) DTT TNFRSF12A 6.05E-05 0.72 1.75
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25.